<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Perazine for schizophrenia - Leucht, S - 2014 | Cochrane Library</title> <meta content="Perazine for schizophrenia - Leucht, S - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002832.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Perazine for schizophrenia - Leucht, S - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002832.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002832.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Perazine for schizophrenia" name="citation_title"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Stefan.Leucht@lrz.tu-muenchen.de" name="citation_author_email"/> <meta content="Bartosz Helfer" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Benno Hartung" name="citation_author"/> <meta content="University Hospital Duesseldorf" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD002832.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002832.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002832.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002832.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Perazine [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002832.pub3&amp;doi=10.1002/14651858.CD002832.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002832\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002832\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","pl","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002832.pub3",title:"Perazine for schizophrenia",firstPublishedDate:"Jan 15, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002832.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002832.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002832.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002832.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002832.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002832.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002832.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002832.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002832.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002832.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1663 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002832.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0157"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0099"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-sec-0140"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/appendices#CD002832-sec-0165"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/table_n/CD002832StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/table_n/CD002832StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Perazine for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information#CD002832-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Stefan Leucht</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information#CD002832-cr-0003">Bartosz Helfer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information#CD002832-cr-0004">Benno Hartung</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information/en#CD002832-sec-0171">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002832.pub3">https://doi.org/10.1002/14651858.CD002832.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002832-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002832-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002832-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002832-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002832-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002832-abs-0001" lang="en"> <section id="CD002832-sec-0001"> <h3 class="title" id="CD002832-sec-0001">Background</h3> <p>Perazine is an old phenothiazine derivative used for the treatment of people with schizophrenia and is reputed to have a low level of extrapyramidal adverse effects. As far as we are aware, its use is limited to Germany, Poland, the former Yugoslavia and the Netherlands. </p> </section> <section id="CD002832-sec-0002"> <h3 class="title" id="CD002832-sec-0002">Objectives</h3> <p>To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications. </p> </section> <section id="CD002832-sec-0003"> <h3 class="title" id="CD002832-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group Trials Register, which includes relevant randomised controlled trials from the bibliographic databases Biological Abstracts, CINAHL, <i>The Cochrane Library</i>, EMBASE, MEDLINE, PsycLIT, LILACS, PSYNDEX, Sociological Abstracts and Sociofile. We searched the references of all included studies for further trials. We contacted pharmaceutical companies and authors of trials. We updated this search on 16th July 2012. </p> </section> <section id="CD002832-sec-0004"> <h3 class="title" id="CD002832-sec-0004">Selection criteria</h3> <p>We selected all randomised controlled trials that compared perazine with other treatments for people with schizophrenia or schizophrenia‐like psychoses, or both. </p> </section> <section id="CD002832-sec-0005"> <h3 class="title" id="CD002832-sec-0005">Data collection and analysis</h3> <p>The review authors (SL, BH, BHe) independently inspected the citations and where possible abstracts and ordered papers for re‐inspection and quality assessment. We independently extracted data. We calculated the risk ratio (RR) and 95% confidence interval (CI) using a random‐effects model. For continuous data, we calculated mean differences (MD). We inspected all data for heterogeneity, assessed trials for risk of bias and created summary of findings tables using GRADE. </p> </section> <section id="CD002832-sec-0006"> <h3 class="title" id="CD002832-sec-0006">Main results</h3> <p>The review now includes seven trials with a total of 479 participants. In only one trial, with 95 participants, perazine appeared superior to 'active placebo' (trimipramine) at five weeks for the outcome of 'no important global improvement' (n = 95, RR 0.43 CI 0.2 to 0.8, <i>low quality evidence</i> ), but there was no statistically significant difference in most measures of mental state. Perazine did not induce more general adverse events than placebo but more participants received at least one dose of antiparkinson medication (n = 95, RR 4.50 CI 1.0 to 19.5, <i>very low quality evidence</i>). </p> <p>Six small trials comparing perazine with other antipsychotics, including 384 participants in total, were incompletely reported and the outcomes were presented in various ways so that meta‐analysis was not possible on most occasions. In the six studies, a similar number of participants receiving perazine or comparator antipsychotics (amisulpride, haloperidol, olanzapine, ziprasidone, zotepine) left the studies early (n = 384, RR 0.97 CI 0.68 to 1.38, <i>low quality evidence</i>). The results on efficacy could not be meta‐analysed because the authors presented their results in very different ways. No obvious differences in adverse events between perazine and other antipsychotics could be derived from the limited data. Two haloperidol comparisons did not present extrapyramidal side‐effects in a way that was suitable for use in meta‐analysis, but three small comparisons with the second‐generation antipsychotics zotepine and amisulpride showed no higher risk of akathisia (n = 111, RR 0.31 CI 0.1 to 1.1), dyskinesia (n = 111, RR 0.47 CI 0.1 to 3.5), parkinsonism (n = 81, RR 1.21 CI 0.5 2.8) or tremor (n = 40, RR 0.80 CI 0.3 to 2.6) with perazine. </p> </section> <section id="CD002832-sec-0007"> <h3 class="title" id="CD002832-sec-0007">Authors' conclusions</h3> <p>The number, size and reporting of randomised controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side‐effects as some atypical antipsychotics but this is based on small comparisons. This should be clarified in larger, well‐designed trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002832-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002832-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002832-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002832-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002832-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002832-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002832-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002832-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002832-abs-0004" lang="en"> <h3>Perazine for schizophrenia</h3> <p>Schizophrenia is often a severe and disabling illness that affects approximately one per cent of the worldwide population. Schizophrenia has 'positive' symptoms, such as strange and fixed beliefs (delusions), as well as hearing voices and seeing things (hallucinations). Schizophrenia also has 'negative' symptoms such as apathy, loss of emotion, lack of drive and disorganisation of behaviour and thought. The degree of disability is considerable with 80% ‐ 90% not working and up to 10% dying. </p> <p>Antipsychotic drugs are the main treatment for schizophrenia, and are grouped into older drugs (first generation or ‘typical’) and newer drugs (second generation or ‘atypical’). However, antipsychotic drugs also have serious side effects, particularly movement disorders such as uncontrollable shaking, tremors, muscle stiffness, tiredness, weight gain and the inability to sit still. </p> <p>Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia. </p> <p>A search for trials was carried out in July 2012. The review now includes seven studies with a total of 479 participants and assesses the effects of perazine for people with schizophrenia. Comparisons of perazine versus placebo (‘dummy’ treatment) and versus other antipsychotic drugs revealed no clear differences or superiority of perazine. However, only a handful of studies have been undertaken and the number of participants in each study was small. In addition the studies avialable were of limited quality with data for the main outcomes of interest rated as low or very low quality. As perazine is a cheap drug and there is some limited evidence that it may cause less side effects than other older antipsychotic drugs, further large scale, well designed and well‐reported studies are much needed. </p> <p>This plain language summary has been written by a consumer Benjamin Gray from Rethink Mental Illness, </p> <p>Email: <a href="http://mailto:ben.gray@rethink.org" target="_blank"><span class="__cf_email__" data-cfemail="e88a8d86c68f9a8991a89a8d9c80818683c6879a8f">[email protected]</span></a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002832-sec-0157" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002832-sec-0157"></div> <h3 class="title" id="CD002832-sec-0158">Implications for practice</h3> <section id="CD002832-sec-0158"> <section id="CD002832-sec-0159"> <h5 class="title">1. For clinicians</h5> <p>Clinicians should be aware that perazine is an antipsychotic with a very limited dataset concerning the evidence from randomised controlled trials. The available data do not allow a clear judgement on whether it is more or less effective than other currently used antipsychotics. Although perazine is said to be associated with fewer extrapyramidal side‐effects than high‐potency conventional antipsychotics, the necessary information could not be extracted from the few randomised controlled trials that are available. However, in three small trials perazine was not associated with more extrapyramidal side‐effects than zotepine and amisulpride. Therefore perazine might have a similar risk for movement disorders as these second‐generation antipsychotics, but larger trials are needed to confirm this hypothesis. </p> </section> <section id="CD002832-sec-0160"> <h5 class="title">2. For people with schizophrenia</h5> <p>People with schizophrenia should be aware that although German and Polish psychiatrists have more than 30 years experience of treating patients with perazine, there exists only very limited evidence from randomised controlled trials on its effectiveness and its tolerability. </p> </section> <section id="CD002832-sec-0161"> <h5 class="title">3. For managers, founders, decision makers</h5> <p>They should be aware that perazine is a cheap antipsychotic which possibly has atypical properties (low extrapyramidal symptom risk) and that it is worth examining perazine in randomised trials. Indeed, the most recent randomised controlled trial found no major difference in efficacy and numbers leaving the study early between perazine and olanzapine or ziprasidone (<a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>). </p> </section> </section> <h3 class="title" id="CD002832-sec-0162">Implications for research</h3> <section id="CD002832-sec-0162"> <p>The trials that were reviewed predated the CONSORT statement (<a href="./references#CD002832-bbs2-0034" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT Statement. JAMA1996;276(8):637‐9. ">Begg 1996</a>). Had this been anticipated more data may have been available to inform practice. However, even with better reporting of the trials, the possibility of drawing firm conclusions would have been limited due to the low number of participants that were included (479). Since there seems to be an indication that perazine might have similar properties to some of the newer second‐generation antipsychotics, in terms of movement disorders, further well‐designed studies are called for. See also <a href="#CD002832-tbl-0003">Table 1</a>. </p> <div class="table" id="CD002832-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: 3 months, 12 months open follow‐up. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia with acute exacerbation.<br/> N = 900.*<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Perazine: dose 300‐800 mg/day. N = 300.</p> <p>2. Haloperidol: dose 2‐15 mg/day. N = 300.</p> <p>3. Olanzapine: dose 5‐20mg/day. N = 300.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving study early (any reason, adverse events, inefficacy).<br/> Service outcomes: hospitalised, time in hospital, attending out patient clinics.<br/> Global impression: Number of participants much improved (CGI)**.<br/> Mental state: PANSS. </p> <p>Quality of life, subjective well‐being.<br/> Adverse events. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> <br/> ** Primary outcome </p> </div> </div> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002832-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002832-sec-0022"></div> <div class="table" id="CD002832-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Perazine versus placebo for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perazine versus placebo for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> perazine versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Perazine versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> <br/> Leaving the study early due to any reason<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>422 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>262 per 1000</b> <br/> (148 to 464) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/> (0.35 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state</b> <br/> change over time (no better or deterioration)<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> <br/> (107 to 378) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/> (0.23 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mental state</b> <br/> less than 30% BPRS reduction<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>733 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>601 per 1000</b> <br/> (447 to 799) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> <br/> (0.61 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Movement disorders</b> <br/> number of participants receiving antiparkinson medication<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (46 to 864) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.5</b> <br/> (1.04 to 19.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall tolerability</b> <br/> Leaving the studies early due to adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: high risk of attrition bias.<br/> <sup>2</sup> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.<br/> <sup>3</sup> Imprecision: very small number of events.<br/> <sup>4</sup> Indirectness: movement disorders were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002832-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Perazine versus other antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perazine versus other antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> mainly hospital<br/> <b>Intervention:</b> perazine versus other antipsychotics </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Perazine versus other antipsychotics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state</b> <br/> change over time (no better or deterioration)<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (72 to 994) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> <br/> (0.36 to 4.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mental state</b> <br/> BPRS endpoint score. Scale from: 0 to 108.<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall mental state in the control groups was<br/> <b>BPRS endpoint score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall mental state in the intervention groups was<br/> <b>0.4 lower</b> <br/> (0.74 to 0.06 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Movement disorders</b> <br/> number of participants receiving antiparkinson medication<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>242 per 1000</b> <br/> (106 to 552) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (0.53 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall tolerability</b> <br/> Leaving the study early due to adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (51 to 240) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/> (0.4 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> <br/> Leaving the studies early due to any reason<br/> Follow‐up: 1‐3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> <br/> (202 to 409) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/> (0.68 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: high risk of reporting bias.<br/> <sup>2</sup> Imprecision: Small number of events.<br/> <sup>3</sup> Imprecision: Very small population size.<br/> <sup>4</sup> Indirectness: adverse events were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events.<br/> <sup>5</sup> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002832-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002832-sec-0023"></div> <section id="CD002832-sec-0024"> <h3 class="title" id="CD002832-sec-0024">Description of the condition</h3> <p>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately 1% of the population worldwide with few gender differences. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations); 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought; and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD002832-bbs2-0038" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% of those affected not working (<a href="./references#CD002832-bbs2-0063" title="MarwahaS , JohnsonS . Schizophrenia and employment? A review. Social Psychiatry and Psychiatric Epidemiology 224;39:337‐49. ">Marvaha 2004</a>) and up to 10% dying (<a href="./references#CD002832-bbs2-0068" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153‐55. ">Tsuang 1978</a>). </p> </section> <section id="CD002832-sec-0025"> <h3 class="title" id="CD002832-sec-0025">Description of the intervention</h3> <p>Perazine is a phenothiazine derivative which has been used as an antipsychotic in Germany since 1958. It is usually taken by mouth but an intramuscular formulation for the rapid treatment of very acutely disturbed psychotic patients is also available. It was developed and tested soon after chlorpromazine in the 1950s. </p> <p>The customary dose range recommended for this antipsychotic under inpatient conditions is 75 to 600 mg/day (maximum 1000 mg/day). In acutely ill and severely disturbed patients, 50 mg perazine at time intervals of 30 minutes can be administered intramuscularly (<a href="./references#CD002832-bbs2-0035" title="BenkertO , HippiusH . Psychiatrische Pharmakotherapie. 6th Edition. Berlin: Springer Verlag, 1996. ">Benkert 1996</a>). </p> </section> <section id="CD002832-sec-0026"> <h3 class="title" id="CD002832-sec-0026">How the intervention might work</h3> <p>Perazine has a dopamine receptor binding action, which is similar to that of chlorpromazine and lower than that of haloperidol (<a href="./references#CD002832-bbs2-0067" title="SeemanP . Brain dopamine receptors. Pharmacological Review1981;32:3. ">Seeman 1981</a>). This suggests that the risk of extrapyramidal adverse effects should be lower than high potency antipsychotics such as haloperidol. This low risk of extrapyramidal adverse effects might also be enhanced by a rather high binding affinity for cholinergic receptors that counteract dopamine receptor blockade (<a href="./references#CD002832-bbs2-0064" title="MengeHG , BrandU . not available [Pharmakologie von Perazin und seinen Hauptmetaboliten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart/New York: Georg Thieme Verlag, 1988:9‐13. ">Menge 1988</a>). Perazine is also a potent inhibitor of central histaminergic receptors, which explains its sedating effects. These can be of benefit in the case of psychotic agitation (<a href="./references#CD002832-bbs2-0064" title="MengeHG , BrandU . not available [Pharmakologie von Perazin und seinen Hauptmetaboliten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart/New York: Georg Thieme Verlag, 1988:9‐13. ">Menge 1988</a>). Antagonistic effects on alpha‐1 adrenergic receptors can be associated with cardiovascular adverse effects. Perazine has two metabolites, desmethyl‐perazin and perphenazine‐sulfoxide, which do not seem to have clinically significant effects (<a href="./references#CD002832-bbs2-0064" title="MengeHG , BrandU . not available [Pharmakologie von Perazin und seinen Hauptmetaboliten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart/New York: Georg Thieme Verlag, 1988:9‐13. ">Menge 1988</a>). </p> </section> <section id="CD002832-sec-0027"> <h3 class="title" id="CD002832-sec-0027">Why it is important to do this review</h3> <p>Early uncontrolled studies of perazine suggested good efficacy for the treatment of acutely ill people with schizophrenia (<a href="./references#CD002832-bbs2-0047" title="EnssH , HartmannK , RichterH‐E . not available [Klinische Erfahrungen mit einem neuen Piperazin‐Derivat des Phenothiazins in der Neuro‐Psychiatrie]. Archiv für Neurologie und Nervenkrankheiten1958;197:534. ">Enss 1958</a>). Other open studies evaluated the use of perazine for antipsychotic relapse prevention and yielded promising results, especially as the rate of extrapyramidal adverse effects appeared to be low (<a href="./references#CD002832-bbs2-0054" title="HippiusH . Long‐term pharmacotherapy of schizophrenia. Proceedings of the II International Conference of the Manfred Sakel Foundation. New York: CC Page and Co, 1962. ">Hippius 1962</a>; <a href="./references#CD002832-bbs2-0058" title="KrügerHJ , SchwarzH . not available [Neue Aspekte der psychiatrischen Langzeittherapie in der psychiatrischen Ambulanz und Klinik]. Medizinische Welt1963;9:463‐7. ">Krüger 1963</a>; <a href="./references#CD002832-bbs2-0049" title="GrohmannR , KochR , RütherE , SchmidtLG . not available [Nebenwirkungen von Perazin im Vergleich zu anderen Neuroleptika]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart/New York: Georg Thieme Verlag, 1988:74‐83. ">Grohmann 1988</a>). However, although perazine is frequently used in Germany, we understand its current use is limited to only a few other countries, Poland, the Netherlands and former Yugoslavia. We felt it important to evaluate the evidence derived from randomised controlled trials of an antipsychotic with regionally restricted use. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002832-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002832-sec-0028"></div> <p>To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002832-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002832-sec-0029"></div> <section id="CD002832-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002832-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials.</p> </section> <section id="CD002832-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included people with the diagnosis of schizophrenia, however diagnosed. We also included those with 'serious or chronic mental illness' or 'psychotic illness'. If possible, we excluded people with schizoaffective disorder, dementing illnesses, depression and problems primarily associated with substance misuse. </p> </section> <section id="CD002832-sec-0033"> <h4 class="title">Types of interventions</h4> <p>1. Perazine monotherapy, any dose and pattern of administration. If different doses of perazine were randomised, we included these studies if there was also a comparison with a second drug, placebo or no treatment.<br/> 2. Placebo or no treatment.<br/> 3. Monotherapy with other antipsychotic drugs, any dose or pattern of administration. </p> </section> <section id="CD002832-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>As schizophrenia is often a lifelong illness and perazine is used as an ongoing treatment, we grouped outcomes according to time periods: short term (up to three months), medium term (three months to one year) and long term (more than one year). </p> <section id="CD002832-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD002832-sec-0036"> <h6 class="title">1. Clinical response</h6> <p>1.1 Clinically significant response in global state ‐ as defined by each of the studies (short term) </p> </section> </section> <section id="CD002832-sec-0037"> <h5 class="title">Secondary outcomes</h5> <section id="CD002832-sec-0038"> <h6 class="title">1. Death ‐ suicide or natural causes</h6> </section> <section id="CD002832-sec-0039"> <h6 class="title">2. Leaving the study early</h6> </section> <section id="CD002832-sec-0040"> <h6 class="title">3. Service utilisation</h6> <p>3.1 Hospital admission<br/> 3.2 Days in hospital<br/> 3.3 Change in hospital status </p> </section> <section id="CD002832-sec-0041"> <h6 class="title">4. Mental state</h6> <p>4.1 Clinically significant response in mental state ‐ as defined by each of the studies<br/> 4.2 Average score or change in mental state<br/> 4.3 Clinically significant response on positive symptoms ‐ as defined by each of the studies<br/> 4.4 Average score or change in positive symptoms<br/> 4.5 Clinically significant response on negative symptoms ‐ as defined by each of the studies<br/> 4.6 Average score or change in negative symptoms </p> </section> <section id="CD002832-sec-0042"> <h6 class="title">5. Behaviour</h6> <p>5.1 Clinically significant response in behaviour (e.g. aggressive behaviour, behaviour on the ward etc.) ‐ as defined by each of the studies<br/> 5.2 Average score or change in behaviour </p> </section> <section id="CD002832-sec-0043"> <h6 class="title">6. Extrapyramidal adverse effects</h6> <p>6.1 Incidence of use of antiparkinson drugs<br/> 6.2 Clinically significant extrapyramidal adverse effects ‐ as defined by each of the studies<br/> 6.3 Average score or change in extrapyramidal side‐effects </p> </section> <section id="CD002832-sec-0044"> <h6 class="title">7. Other adverse effects, general and specific</h6> <p>7.1 Number of people dropping out due to adverse affects<br/> 7.2 Cardiac effects<br/> 7.3 Anticholinergic effects<br/> 7.4 Antihistamine effects<br/> 7.5 Prolactin related symptoms </p> </section> <section id="CD002832-sec-0045"> <h6 class="title">8. Social functioning</h6> <p>8.1 Clinically significant response in social functioning ‐ as defined by each of the studies<br/> 8.2 Average score or change in social functioning </p> </section> <section id="CD002832-sec-0046"> <h6 class="title">9. Economic outcomes</h6> <p>10. Quality of life or satisfaction with care for either recipients of care or carers<br/> 10.1 Significant change in quality of life or satisfaction ‐ as defined by each of the studies<br/> 10.2 Average score or change in quality of life or satisfaction<br/> 10.3 Employment status </p> </section> <section id="CD002832-sec-0047"> <h6 class="title">11. Cognitive functioning.</h6> </section> <section id="CD002832-sec-0048"> <h6 class="title">12. Summary of findings table</h6> <p>We used the <a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADE</a>approach to interpret findings (<a href="./references#CD002832-bbs2-0066" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used the <a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADE</a> profiler to import data from Review Manager (<a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes that we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the summary of findings table. </p> <p>1. Global state.</p> <p>2. Mental state (overall) ‐ clinically significant response in mental state, as defined by each of the studies. </p> <p>3. Acceptability of treatment (leaving the study early due to any reason).</p> <p>4. Overall tolerability (leaving the study early due to adverse events).</p> <p>5. Movement disorders (number of participants receiving antiparkinson medication at least once). </p> <p>6. Satisfaction with care.</p> <p>7. Quality of life.</p> </section> </section> </section> </section> <section id="CD002832-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <p>Search methods for this 2012 update are below, for previous searches please see the <a href="#CD002832-sec-0165">Appendices</a>. </p> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD002832-sec-0050"> <h4 class="title">Electronic searches</h4> <section id="CD002832-sec-0051"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register</h5> <p>The Trials Search Co‐ordinator searched the Cochrane Schizophrenia Group Trials Register (16th July 2012). </p> <section id="CD002832-sec-0052"> <h6 class="title">1.1 Intervention search</h6> <p>The ‘Intervention’ field was searched using the phrase:</p> <p>(*perazin* or *pernazin* or *taxilan* or *phenothiazine tran* or * piperazin*).</p> <p>The Cochrane Schizophrenia Group Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). Incoming trials are screened by the Trial Search Co‐ordinator and assigned to the awaiting classification section of relevant existing or new review titles. </p> </section> </section> </section> <section id="CD002832-sec-0053"> <h4 class="title">Searching other resources</h4> <section id="CD002832-sec-0054"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all identified studies for more citations.</p> </section> <section id="CD002832-sec-0055"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for more information regarding unpublished trials. </p> </section> <section id="CD002832-sec-0056"> <h5 class="title">3. Drug company</h5> <p>We contacted the manufacturers of proprietary perazine (Lundbeck, Kopenhagen) for additional data (first version only, not done for updates). </p> </section> </section> </section> <section id="CD002832-sec-0057"> <h3 class="title" id="CD002832-sec-0057">Data collection and analysis</h3> <p>Methods used in data collection and analysis for this 2012 update are below, for previous methods please see <a href="#CD002832-sec-0165">Appendices</a>. </p> <section id="CD002832-sec-0058"> <h4 class="title">Selection of studies</h4> <p>For this 2012 update the review authors SL and BHe independently inspected citations from the new electronic search and identified relevant abstracts. SL and BHe also inspected full articles of the abstracts which might have met the inclusion criteria. </p> </section> <section id="CD002832-sec-0059"> <h4 class="title">Data extraction and management</h4> <section id="CD002832-sec-0060"> <h5 class="title">1. Extraction</h5> <p>Review authors SL and BH extracted the data from the included studies (first version, there were no new included studies in the 2012 update). We extracted data presented only in graphs and figures whenever possible. When further information was necessary, we contacted the authors of studies in order to obtain missing data or for clarification. </p> </section> <section id="CD002832-sec-0061"> <h5 class="title">2. Management</h5> <section id="CD002832-sec-0062"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD002832-sec-0063"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD002832-bbs2-0062" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally the measuring instrument should either be: i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in the 'Description of studies'. </p> </section> <section id="CD002832-sec-0064"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided to primarily use endpoint data, and to only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout the review (section 9.4.5.2 of <a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). </p> </section> <section id="CD002832-sec-0065"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: </p> <p>a) standard deviations and means are reported in the paper or obtainable from the authors; </p> <p>b) when a scale starts from the finite number zero the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD002832-bbs2-0033" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. [PER170800] ">Altman 1996</a>)); </p> <p>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD &gt; (S ‐ S min), where S is the mean score and S min is the minimum score. </p> <p>Endpoint scores on scales often have a finite start and endpoint, and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in 'Other tables' within the 'Data and analyses' section rather than into a statistical analysis. Skewed data pose less of a problem when looking at the mean if the sample size is large; we entered such endpoint data into the syntheses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses regardless of the size of the study. </p> </section> <section id="CD002832-sec-0066"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparisons between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (for example mean days per month). </p> </section> <section id="CD002832-sec-0067"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS) (<a href="./references#CD002832-bbs2-0065" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD002832-bbs2-0057" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>) this could be considered as a clinically significant response (<a href="./references#CD002832-bbs2-0059" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005</a>; <a href="./references#CD002832-bbs2-0060" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD002832-sec-0068"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for perazine. </p> </section> </section> </section> <section id="CD002832-sec-0069"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this 2012 update, BHe worked independently by using the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. SL supervised the process. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where adequate details of randomisation and other characteristics of the trials were not provided, we contacted the authors of the studies in order to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD002832-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD002832-sec-0070"> <h4 class="title">Measures of treatment effect</h4> <section id="CD002832-sec-0071"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD002832-bbs2-0037" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD002832-bbs2-0040" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat or harm (NNT or H) statistic with its confidence interval is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and its interpretation (<a href="./references#CD002832-bbs2-0055" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British journal of haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD002832-sec-0072"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated the mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). If scales of very considerable similarity were used, we presumed there was a small difference in measurement and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD002832-sec-0073"> <h4 class="title">Unit of analysis issues</h4> <section id="CD002832-sec-0074"> <h5 class="title">1. Cluster randomised trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data pose problems. Authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD002832-bbs2-0041" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD002832-bbs2-0036" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD002832-bbs2-0050" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and to adjust for this using accepted methods (<a href="./references#CD002832-bbs2-0050" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we presented these data as if from a non‐cluster randomised study but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra‐class correlation coefficient (ICC) [Design effect = 1 + (m ‐ 1) * ICC] (<a href="./references#CD002832-bbs2-0042" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported it was assumed to be 0.1 (<a href="./references#CD002832-bbs2-0069" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed, taking into account intra‐class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD002832-sec-0075"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (for example pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD002832-bbs2-0045" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used the data of the first phase of cross‐over studies. </p> </section> <section id="CD002832-sec-0076"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary we simply added these and combined them within the two‐by‐two table. If data were continuous we combined the data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD002832-sec-0077"> <h4 class="title">Dealing with missing data</h4> <section id="CD002832-sec-0078"> <h5 class="title">1. Overall loss of credibility</h5> <p>We agree that at some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD002832-bbs2-0070" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). It is, however, unclear from which degree of loss to follow‐up this becomes a problem. We therefore did not exclude studies on the basis of loss to follow‐up. </p> </section> <section id="CD002832-sec-0079"> <h5 class="title">2. Binary</h5> <p>We presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). Those leaving the study early were assumed to have remained unchanged. This assumption is conservative for measures of response because those leaving the study early are assumed to have not responded. It is not conservative for side‐effects. We however felt that it would often be an overestimation of the risk if all participants who left the studies early were assumed to have developed a side‐effect. </p> </section> <section id="CD002832-sec-0080"> <h5 class="title">3. Continuous</h5> <section id="CD002832-sec-0081"> <h6 class="title">3.1 Attrition</h6> <p>We aimed to extract intention‐to‐treat data, but if these were not available we presented and used the data from the people who completed the study. </p> </section> <section id="CD002832-sec-0082"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but exact standard errors and confidence intervals available for group means, and either P values or T values available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we would calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD002832-bbs2-0048" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD002832-sec-0083"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD002832-bbs2-0061" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). We reproduced these data but readers should be aware of the problem. </p> </section> </section> </section> <section id="CD002832-sec-0084"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD002832-sec-0085"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We initially considered all included studies, without seeing the comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed them. </p> </section> <section id="CD002832-sec-0086"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We initially considered all included studies, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed them. </p> </section> <section id="CD002832-sec-0087"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD002832-sec-0088"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD002832-sec-0089"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> statistic alongside the Chi<sup>2</sup> test P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD002832-bbs2-0052" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on: i. the magnitude and direction of the effects and ii. strength of evidence for heterogeneity (for example P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD002832-sec-0092">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD002832-sec-0090"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD002832-bbs2-0044" title="EggerM , Davey‐SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple graphical test. BMJ1997;315:629‐35. ">Egger 1997</a>). These are described in section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002832-bbs2-0053" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD002832-sec-0091"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects model method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. To us this often seems to be true, and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model as it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose the random‐effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed‐effect model. </p> </section> <section id="CD002832-sec-0092"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD002832-sec-0093"> <h5 class="title">1. Subgroup analyses</h5> <p>We proposed to undertake this review and provide an overview of the effects of perazine for people with schizophrenia in general. Information about subgroups (including first episode of the illness, elderly patients, and patients with subtypes of schizophrenia) was missing in the available set of data. </p> </section> <section id="CD002832-sec-0094"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First we investigated whether the data had been entered correctly. Second, if the data were correct, we looked to see if there were methodological reasons in the studies that accounted for the heterogeneity. Finally, the graph was visually inspected and studies outside of the company of the rest were successively removed to see if heterogeneity was restored. When unanticipated clinical or methodological heterogeneity was obvious we simply stated hypotheses regarding the heterogeneity for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD002832-sec-0095"> <h4 class="title">Sensitivity analysis</h4> <p>We applied all sensitivity analyses to the primary outcomes of this review.</p> <section id="CD002832-sec-0096"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when the implied randomised studies were added to those with a better description of randomisation, then we entered all data from these studies. </p> </section> <section id="CD002832-sec-0097"> <h5 class="title">2. Imputed values</h5> <p>We also undertook a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool the data from the excluded trials with the other trials contributing to the outcome but presented them separately. </p> </section> <section id="CD002832-sec-0098"> <h5 class="title">5. Fixed‐effect and random‐effects models</h5> <p>All data were synthesised using a random‐effects model, however we also synthesised the data for the primary outcome using a fixed‐effect model to evaluate whether the greater weights assigned to larger trials with greater event rates altered the significance of the results compared to the more evenly distributed weights in the random‐effects model. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002832-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002832-sec-0099"></div> <section id="CD002832-sec-0100"> <h3 class="title">Description of studies</h3> <p>For a substantive description of studies please see the <a href="./references#CD002832-sec-0176" title="">Characteristics of included studies</a> and <a href="./references#CD002832-sec-0177" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD002832-sec-0101"> <h4 class="title">Results of the search</h4> <p>Please compare with <a href="#CD002832-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002832-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD002832-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD002832-sec-0102"> <h5 class="title">1. Original search in 2000</h5> <p>The original search of the Cochrane Schizophrenia Group (CSG) controlled Trials Register in the year 2000 yielded 40 studies ,which we ordered and inspected. After handsearching included trials and contacting the manufacturers of perazine, we did not identify any further trials. Sixteen publications of six studies met our inclusion criteria. Our contact with the first authors of the studies yielded no further studies or individual patient data. </p> </section> <section id="CD002832-sec-0103"> <h5 class="title">1. Update search in 2005</h5> <p>The update search in the CSG controlled Trials Register in 2005 yielded 59 references. The vast majority of the references were clearly not related to perazine and hence we did not record them in the excluded studies table. We identified three references in two studies (<a href="./references#CD002832-bbs2-0019" title="KemperdickKT , NielingC , SteinigA . not available [Behandlung schizophrener Psychosen mit schwach potenten Neuroleptika]. Medizinische Klinik1967;62:1512‐4. ">Kemperdick 1967</a>; <a href="./references#CD002832-bbs2-0021" title="LozaB , Kucharska‐PieturaK , DebowskaG . Atypical versus typical antipsychotic treatment prognosis in first‐episode paranoid schizophrenia based on wcst and dichotic listening scores. European Neuropsychopharmacology2001;11(3):285. [14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2103#] MazurekI , LozaB , LecykA . Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia. Journal of the European College of Neuropsychopharmacology2003;13(4):S347. [P.2.156] ">Loza 2001</a>) that were classified as excluded studies. We identified three further references in studies that had already been included in the first version. Most noteworthy was the final journal publication of <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>. In contrast to the previously available abstracts and short versions of the trial, further outcome data were presented and some of the previously listed results had to be slightly changed because they were more clearly reported within the new reference. </p> </section> <section id="CD002832-sec-0104"> <h5 class="title">1. Update search in 2012</h5> <p>The update search in 2012, made using the CSG controlled Trials Register, yielded four new references. Three studies did not meet the inclusion criteria. One was an additional publication of a study that had already been included (<a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a>), one was not randomised and it was unclear whether the substance tested was perazine (<a href="./references#CD002832-bbs2-0015" title="GersonIM , ChatE , TwiggerNA . Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients. American Journal of Psychiatry1964;121:179‐81. [MEDLINE: 14196596] ">Gerson 1964</a>), and one used an inappropriate comparison (<a href="./references#CD002832-bbs2-0022" title="OhlmeierMD , JahnK , Wilhelm‐GosslingC , Godecke‐KochT , HoffmannJ , SeifertJ , et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology2007;55(2):81‐8. [MEDLINE: 17570951] ">Ohlmeier 2007</a>). The fourth study was a randomised, open trial comparing perazine with olanzapine and ziprasidone that met the inclusion criteria (<a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>). </p> </section> </section> <section id="CD002832-sec-0105"> <h4 class="title">Included studies</h4> <p>We included seven studies. Six trial centres were in Germany, one was in Poland.</p> <section id="CD002832-sec-0106"> <h5 class="title">1. Methods</h5> <p>All included studies were described as randomised. Follow‐up periods ranged from 28 to 84 days. All seven were short term (up to three months). </p> </section> <section id="CD002832-sec-0107"> <h5 class="title">2. Participants</h5> <p>All but one study (<a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>) of the included studies had less than 100 participants; the range was 23 to 191. A total of 479 people participated in the seven trials, most of whom had a diagnosis of schizophrenia. <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a> also included participants with schizophreniform disorder, and <a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a> also included participants with schizophrenia‐like disorders (for example schizoaffective disorder). We included these studies because the majority of randomised participants had schizophrenia. </p> <p>Five studies used International Classification of Diseases‐9 (ICD‐9) criteria, <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a> used Diagnostic and Statistical Manual of Mental Disorders‐III‐R (DSM‐III‐R), and <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a> used ICD‐10. <a href="./references#CD002832-bbs2-0003" title="KlimkeA , KlieserE . Clinical relevance of the test dose model for drug choice and response in acute schizophrenia. Pharmacopsychiatry1992;25:85. KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia [Frühes Ansprechen als Kriterium der Medikamentenwahl bei akuter Schizophrenie]. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>, <a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a> and <a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a> included only "acutely ill" participants, <a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a> restricted inclusion to participants with positive symptoms and <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a> to paranoid schizophrenia. <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a> required a minimum score on the Brief Psychiatric Rating Scale (BPRS). </p> <p>From those studies that included information on the gender of participants there were 169 males and 174 females. Ages ranged from 18 to 70 years; where the mean age was indicated it ranged between 31 and 37 years. </p> </section> <section id="CD002832-sec-0108"> <h5 class="title">3. Setting</h5> <p>Five studies were from inpatient settings. In two studies (<a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a>; <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>) the setting was not clear. </p> </section> <section id="CD002832-sec-0109"> <h5 class="title">4. Interventions</h5> <p>The dose of perazine ranged between 75 and 1000 mg/day, with means between 300 and 650 mg/day where reported. </p> <p>Only one study (<a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>) was considered to be placebo‐controlled. The comparator group received a tricyclic antidepressant, trimipramine. It turned out to be statistically significantly less effective than perazine at least according to the global impression of the raters. It was regarded as an active placebo. </p> <p>Two studies compared perazine with oral haloperidol. Four studies compared perazine with the second‐generation antipsychotics zotepine (<a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a>; <a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a>), amisulpride (<a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a>), and ziprasidone and olanzapine in <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>, which was a three‐arm study. In these trials perazine was used as the gold standard for the evaluation of the second‐generation antipsychotics. </p> </section> <section id="CD002832-sec-0110"> <h5 class="title">5. Outcomes</h5> <p>Many outcomes were presented as scale‐derived, continuous data. Often we could not use the data for meta‐analytic calculations because they were either skewed or the standard deviations were not indicated. Despite letters sent to the study authors (not done for the 2012 update), no original patient data that could have been dichotomised were obtained. </p> </section> <section id="CD002832-sec-0111"> <h5 class="title">6. Scales</h5> <p>Details of the scales that provided usable data are shown below.</p> <section id="CD002832-sec-0112"> <h6 class="title">6.1. Global state</h6> <section id="CD002832-sec-0113"> <p><b>6.1.1 Clinical Global Impression (CGI)</b></p> <p>CGI (<a href="./references#CD002832-bbs2-0051" title="GuyW , BonatoRR . Clinical Global Impressions. Manual for the ECDEU Assessment Battery, 2. Rev ed. National Institute of Mental Health, 1970. ">Guy 1976</a>) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven‐point scoring system is usually employed with low scores indicating decreased severity or greater recovery. Usable data were reported by <a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a>. </p> </section> <section id="CD002832-sec-0114"> <p><b>6.1.2 Global Assessment Scale (GAS)</b></p> <p>In the GAS (<a href="./references#CD002832-bbs2-0046" title="EndicottJ , SpitzerRL , FleissJL , CohenJ . The Global Assessment Scale. Archives of General Psychiatry1976;33:766‐71. ">Endicott 1976</a>) a clinician rates the overall functioning of a patient on a scale of 1 to 100. Lower scores indicate poorer functioning. Usable data were reported by <a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a>. </p> </section> </section> <section id="CD002832-sec-0115"> <h6 class="title">6.2. Mental state</h6> <section id="CD002832-sec-0116"> <p><b>6.2.1 Brief Psychiatric Rating Scale (BPRS)</b></p> <p>BPRS (<a href="./references#CD002832-bbs2-0065" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) is a brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a seven‐point scale varying from 'not present' to 'extremely severe', scoring from 0 to 6 or 1 to 7. Scores can range from 0 to 126, with high scores indicating more severe symptoms. Usable data were reported by <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>, <a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a>, <a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a> and <a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a>. </p> </section> <section id="CD002832-sec-0117"> <p><b>6.2.2 Positive and Negative Syndrome Scale (PANSS)</b></p> <p>PANSS (<a href="./references#CD002832-bbs2-0057" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>) is a schizophrenia scale that has 30 items, each of which can be defined on a seven‐point scoring system varying from 1 ‐ absent to 7 ‐ extreme. It can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P), and negative symptoms (PANSS‐N). A low score indicates lesser severity. Useable data (percentage PANSS total score from baseline) were obtained for <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>. </p> </section> </section> <section id="CD002832-sec-0118"> <h6 class="title">6.3. Missing outcomes</h6> <p>Relapse, issues of hospital admission, behaviour, cognitive functions, cost issues, quality of life and satisfaction with care were not addressed in the included studies. </p> </section> </section> </section> <section id="CD002832-sec-0119"> <h4 class="title">Excluded studies</h4> <p>The majority of excluded studies were not stated to be randomised (n = 19). One study was excluded because it did not examine participants with schizophrenia, one used wrong interventions, and three did not provide any useable outcomes. </p> </section> </section> <section id="CD002832-sec-0120"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias please refer to <a href="#CD002832-fig-0002">Figure 2</a> and <a href="#CD002832-fig-0003">Figure 3</a>. Full details of judgements can be seen in the 'Risk of bias' tables. </p> <div class="figure" id="CD002832-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002832-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002832-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002832-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002832-sec-0121"> <h4 class="title">Allocation</h4> <p>In only two studies (<a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>: randomisation schedule generated by a validated computer program, <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>: randomisation programme written by statistician) was the method used to generate random allocation described. These two studies were classified as having a low risk of selection bias. None of the other studies provided a specific method used in the randomisation procedure and thus they were classified as having an unclear risk of selection bias. </p> <p>Although no differences in baseline descriptions of the comparator groups were found on most occasions, the readers were given little assurance that bias was minimised during the allocation procedure in these other trials. </p> <p>As for the allocation concealment, all studies were classified as unclear in this respect except for <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a> (see risk of bias table). </p> </section> <section id="CD002832-sec-0122"> <h4 class="title">Blinding</h4> <p>Precautions taken to ensure blinding were described in three studies. Two used identical capsules (<a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a>; <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>), whereas in the third study blinding was attempted by treating one group with perazine tablets and placebo liquid and the other group with haloperidol liquid and placebo pills (<a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a>). <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a> was an open trial; and the remaining trials reported that they were blind but did not describe the methods of blinding. </p> </section> <section id="CD002832-sec-0123"> <h4 class="title">Incomplete outcome data</h4> <p>In all seven studies data were presented on losses to follow‐up.</p> <p>Although all studies indicated the numbers of participants who left the study before its completion, the reasons for leaving the studies early were not consistently indicated. </p> <p>Two studies were assessed as having a low risk of attrition bias, meaning that the problem of incomplete outcome data was addressed in an appropriate way (the number of dropouts was not very high and was evenly distributed between groups). Another two studies were judged as unclear, and another and the last three as having high risk of attrition bias. </p> </section> <section id="CD002832-sec-0124"> <h4 class="title">Selective reporting</h4> <p>Four out of seven studies were judged as having a high risk of reporting bias due to the lack of information about some predefined outcomes. Standard deviations and means were often missing. The remaining three studies did not selectively report on any outcomes and thus were judged as having a low risk of bias in that respect. </p> </section> <section id="CD002832-sec-0125"> <h4 class="title">Other potential sources of bias</h4> <p>The included studies were free of any other clear sources of bias.</p> </section> </section> <section id="CD002832-sec-0126"> <h3 class="title" id="CD002832-sec-0126">Effects of interventions</h3> <p>See: <a href="./full#CD002832-tbl-0001"><b>Summary of findings for the main comparison</b> Perazine versus placebo for schizophrenia</a>; <a href="./full#CD002832-tbl-0002"><b>Summary of findings 2</b> Perazine versus other antipsychotics for schizophrenia</a> </p> <section id="CD002832-sec-0127"> <h4 class="title">1. Comparison 1: Perazine versus placebo</h4> <p>Ninety‐five participants from one study (<a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>) were randomised to this comparison. </p> <section id="CD002832-sec-0128"> <h5 class="title">1.1 Leaving the study early</h5> <p>No significant difference between perazine and trimipramine was found for the outcome 'leaving the study early for any reason' (n = 95, RR 0.62 CI 0.4to 1.1) and 'due to inefficacy of treatment' (n = 95, RR 0.30 CI 0.09 to 1.04, p = 0.06). The number of participants 'leaving the study early for adverse events' was not indicated. </p> </section> <section id="CD002832-sec-0129"> <h5 class="title">1.2 Global state</h5> <p>For change in global state over time, one small five‐week study (<a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>) demonstrated a statistically significant difference between perazine and the tricyclic antidepressant trimipramine, which was considered to be an active placebo (n = 95, RR 0.43 CI 0.2 to 0.8). The definition of the response criterion was unimproved or worse according to the clinical global impression of the raters. </p> </section> <section id="CD002832-sec-0130"> <h5 class="title">1.3 Mental state</h5> <p>Using a cut‐off of less than 20% BPRS reduction (n = 95, RR 0.70 CI 0.5 to 1.1) or less than 30% BPRS reduction (n = 95, RR 0.82 CI 0.6 to 1.1) no statistically signficant difference in the number of responders was found. The mean BPRS at the endpoint was not significantly different between both groups (n = 79, MD ‐6.20 CI ‐13.2 to 0.8). Results on the mean change of BPRS from baseline to the endpoint differed depending on whether the results were analysed in an intention‐to‐treat or a per protocol analysis. In the former a significant superiority of perazine compared to active placebo was found (n = 95, MD ‐7.10 CI ‐13.5 to ‐0.7), while the latter showed no significant difference (n = 79, MD ‐6.10 CI ‐13.1 to 0.9). Therefore, this result must be interpreted with caution. Further data from two studies on the BPRS at the endpoint (<a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a>) and the Association for Methodology and Documentation in Psychiatry (AMDP) system (<a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a>) could only be presented in 'Other data' tables because they were skewed. </p> </section> <section id="CD002832-sec-0131"> <h5 class="title">1.4 Adverse events</h5> <p>We found no significant differences in terms of 'at least one adverse event' (n = 95, RR 1.15 CI 0.9 to 1.5) and 'at least one extrapyramidal side‐effect' (n = 95, RR 13.53 CI 0.8 to 230.4). However, significantly more people in the perazine group received at least one dose of antiparkinson medication (n = 95, RR 4.50 CI 1.04 to 19.5). </p> </section> <section id="CD002832-sec-0132"> <h5 class="title">1.5 Other outcomes</h5> <p>No data were presented on the other outcomes listed in our methods section.</p> </section> </section> <section id="CD002832-sec-0133"> <h4 class="title">2. Comparison 2: Perazine versus other antipsychotics</h4> <p>A total of 384 patients from six studies were randomised to this comparison. Two studies used haloperidol as a comparator (<a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a>; <a href="./references#CD002832-bbs2-0003" title="KlimkeA , KlieserE . Clinical relevance of the test dose model for drug choice and response in acute schizophrenia. Pharmacopsychiatry1992;25:85. KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia [Frühes Ansprechen als Kriterium der Medikamentenwahl bei akuter Schizophrenie]. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>). The other three studies used atypical antipsychotics, one amisulpride (<a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a>), one olanzapine and ziprasidone (<a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>), and two zotepine (<a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a>; <a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a>), with perazine being used as the gold standard for the evaluation of the atypical antipsychotics. </p> <section id="CD002832-sec-0134"> <h5 class="title">2.1 Leaving the study early</h5> <p>All six studies could be used for the outcome 'leaving the study early' and no difference was found between perazine and the other antipsychotics (n = 384, RR 0.97 CI 0.68 to 1.38). </p> </section> <section id="CD002832-sec-0135"> <h5 class="title">2.2 Global state</h5> <p>According to limited data from one study (<a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a>), participants allocated to perazine were as likely to be 'no better or worse' than those given amisulpride (n = 30, RR 1.33 CI 0.4 to 5.0) but had a higher mean severity of illness according to the Clinical Global Impression Scale (n = 30, MD 1.85 CI 1.01 to 2.7) and a higher severity of illness according to the Global Assessment Scale in the zotepine comparison (n = 41, MD ‐10.0 CI ‐17.1 to ‐2.9). </p> </section> <section id="CD002832-sec-0136"> <h5 class="title">2.3 Mental state</h5> <p>As with the global outcomes, mental state data were reported in a variety of ways hampering comparison.<br/> <a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a> reported no significant difference between perazine and haloperidol on 'no better or worse' (BPRS, n = 32, RR 1.18 CI 0.5 to 2.6). Reporting endpoint BPRS data, <a href="./references#CD002832-bbs2-0007" title="WetzelH , BardelebenU , HolsboerF , BenkertO . Zotepine versus perazine in paranoid schizophrenia: a double‐blind controlled trial of antipsychotic efficacy [Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind‐kontrollierte Wirksamkeitsprüfung]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:23‐9. ">Wetzel 1991</a> showed zotepine as significantly superior to perazine (n = 34, MD 7.92 CI 1.1 to 14.7); however, using a different method to calculate this outcome, <a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a> reported the superiority of perazine compared to zotepine (n = 40, MD ‐0.40 CI ‐0.7 to ‐0.1). If we understand <a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a> correctly, they calculated the mean score of all BPRS items first for each patient and then calculated the mean of all patients. <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a> presented the percentage PANSS total score change from baseline and found no difference between perazine and olanzapine or ziprasidone. </p> <p><a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a> also presented data on the positive symptoms subscore of the BPRS and found significant superiority of perazine compared to zotepine (n = 40, MD ‐0.40, CI ‐0.8 to ‐0.02). </p> <p>The BPRS data from <a href="./references#CD002832-bbs2-0004" title="RütherE , BlankeJ . not available [Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:65‐70. ">Rüther 1988</a> and the AMDP data from <a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a> appeared to be skewed so we were unable to analyse them (numbers are presented in the 'Other data' table). </p> </section> <section id="CD002832-sec-0137"> <h5 class="title">2.4 Adverse events</h5> <p>The reporting of adverse events was incomplete in the included studies. Concerning extrapyramidal side‐effects, no statistically significant differences in terms of akathisia (n = 111, RR 0.31 CI 0.1 to 1.1), dyskinesia (n = 111, RR 0.47 CI 0.1 to 3.5), parkinsonism (n = 81, RR 1.21 CI 0.5 to 2.8) or tremor (n = 80, RR 0.80 CI 0.3 to 2.6) were found between perazine and the atypical antipsychotics zotepine and amisulpride. With the exception of one case of neuroleptic malignant syndrome in the study by <a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a> (equivocal data, n = 32, RR 0.30 CI 0.01 to 6.8) no data on extrapyramidal side‐effects could be used from the three haloperidol comparisons due to poor reporting. </p> <p>A similar number of participants in five studies left the studies earlier due to adverse events (n = 193, RR 0.87 CI 0.4 to 1.9). </p> <p>The incidence of anticholinergic side‐effects (two studies), arousal (one study), orthostatic hypotension (two studies), laboratory abnormalities (three studies), hypersalivation (one study), vegetative disorders (one study), electroencephalogram (EEG) changes (one study) and increase in transaminase (one study) were found to be similar for both groups. However, the equivalence of these two compounds cannot be assumed in this respect due to small numbers and insufficient power. </p> </section> <section id="CD002832-sec-0138"> <h5 class="title">2.5 Other outcomes</h5> <p>No data were presented on all other outcomes listed in our method section.</p> </section> </section> <section id="CD002832-sec-0139"> <h4 class="title">3. Publication bias, subgroup and sensitivity analyses</h4> <p>Due to the paucity of studies we were unable to perform subgroup and sensitivity analyses or tests for publication bias as set out in the methods section. If more trials are published, these analyses will be completed in future updates of this review. The use of the fixed‐effect model did not lead to substantially different results compared to the random‐effects model in terms of the primary outcome. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002832-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002832-sec-0140"></div> <p>Six out of the seven randomised trials were undertaken in Germany, and one in Poland, which limits the generalisability of the results to other countries. Furthermore, most of the studies were undertaken in hospital settings. Although the studies involved people with a clear diagnosis of schizophrenia, it is difficult to make a definite statement on generalisability because the reports do not describe how many patients who would have met the inclusion criteria were not enrolled in the trials. The trials were all classified as short term, so the long‐term effects of perazine for an often chronic disorder were not assessed. Specific data for those presenting with a first episode of the illness, elderly patients, and patients with subtypes of schizophrenia are missing. The limitations in the available data are also reflected in the risk of bias table and the summary of findings table. </p> <section id="CD002832-sec-0141"> <h3 class="title" id="CD002832-sec-0141">Summary of main results</h3> <section id="CD002832-sec-0142"> <h4 class="title">1. Comparison 1: Perazine versus placebo</h4> <section id="CD002832-sec-0143"> <h5 class="title">1.1 General</h5> <p>Surprisingly, the only trial which could be considered as a comparison of perazine with active placebo was the second most recently published one (<a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>); therefore perazine has been used for several decades without evidence derived from randomised controlled trials that it is more effective than placebo. This illustrates the dramatic shift of research paradigms and the recent increase in requirements for new drugs to be prescribed to patients. It is of course debatable whether the comparator in the trial, trimipramine, can be considered to be an 'active placebo'. Trimipramine is a tricyclic antidepressant and antidepressants have not been shown to have important antipsychotic effects. But the hypothesis of the trial was that trimipramine may have such properties because it affects the dopamine system. Given the paucity of data on perazine in general, and since overall perazine was more effective than trimipramine in the study, we decided that for the purpose of this review this classification was acceptable. </p> </section> <section id="CD002832-sec-0144"> <h5 class="title">1.2 Leaving the study early</h5> <p>A similar number of the participants treated with perazine and with trimipramine left the study early. This is surprising as it would be expected that a proper antipsychotic treatment would be more acceptable for those with schizophrenia than an antidepressant. </p> </section> <section id="CD002832-sec-0145"> <h5 class="title">1.3 Global state and mental state</h5> <p>There are very little data, derived from one small trial with 95 participants, to suggest that more people with schizophrenia who are treated with perazine globally improve in the short term than those treated with an antidepressant. However, looking at the mental state result this finding was only confirmed in the intention‐to‐treat analysis of the BPRS change from baseline to endpoint and hence cannot be considered as robust. </p> </section> <section id="CD002832-sec-0146"> <h5 class="title">1.4 Adverse events</h5> <p>Compared to the original version, the update did provide some data on adverse events. While no differences in terms of the number of participants with 'any adverse event' and 'at least one extrapyramidal side‐effect' were found, more participants in the perazine group received antiparkinson medication indicating movement disorders as an adverse event. This result could call into question our hypothesis in the first version of the review that perazine may be an 'atypical antipsychotic'. However, only 20% of people in the perazine group received antiparkinson medication. This is a similar rate to that of atypical antipsychotics such as olanzapine (16%) (<a href="./references#CD002832-bbs2-0043" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a>). The fact that perazine induced significantly more movement disorders than 'active placebo' in this trial may be due to the anticholinergic effects of trimipramine. The studies on atypical antipsychotics used real placebo so that withdrawal extrapyramidal symptoms may have occurred in the placebo groups and obscured any differences between the groups. We would therefore like to maintain the hypothesis that perazine could be an atypical antipsychotic, but given the small amount of available data this is at present mere speculation. </p> </section> </section> <section id="CD002832-sec-0147"> <h4 class="title">2. Comparison 2: Perazine versus other antipsychotics</h4> <section id="CD002832-sec-0148"> <h5 class="title">2.1 General</h5> <p>We were pleasantly surprised that in 2012 another perazine randomised controlled trial has been published, it is the largest included study (<a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>). We welcome the research interest in old compounds such as perazine, which can make valuable contributions to treatment. The overall results of this comparison cannot be regarded as conclusive due to the small numbers randomised to the studies and outcomes that were either poorly presented or presented in different ways that made meta‐analysis impossible. On most occasions only one or two studies reported on an outcome in the same way. </p> </section> <section id="CD002832-sec-0149"> <h5 class="title">2.2 Leaving the study early</h5> <p>In these short‐term studies 28% of those taking perazine and 30% in the control groups left before the trial was completed. This is a relatively low attrition rate compared to some trials dealing with newer antipsychotic drugs. </p> </section> <section id="CD002832-sec-0150"> <h5 class="title">2.3 Global state</h5> <p>No usable data could be extracted from the trials comparing perazine with conventional antipsychotics such as haloperidol, thus it is not clear whether perazine is more or less effective in improving global state. According to two comparisons with the atypical antipsychotics zotepine and amisulpride, perazine faired worse regarding the mean global state of the participants at the end of the studies. Due to the very low number of participants that were randomised in these trials this result cannot be regarded as conclusive without further trials. </p> </section> <section id="CD002832-sec-0151"> <h5 class="title">2.4 Mental state</h5> <p>On analysing a small database containing the results of two trials, perazine had a similar efficacy compared to haloperidol for the improvement of mental state. The data from two studies comparing perazine with the newer antipsychotic zotepine are equivocal; one trial found zotepine to be superior, whereas <a href="./references#CD002832-bbs2-0002" title="AckenheilM , DieterleD , KapfhammerHP , Müller‐SpahnF , HippiusH . not available [Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme Verlag, 1988:60‐4. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , MullerspahnF , et al. A double‐blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic‐patients. International Journal of Neuroscience1987;32(1‐2):438. DieterleDM , AlbusM , BlankeE , EbenE , KleinH , Müller‐Spahn , RütherE . A double‐blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients. 4th World Congress of Biological Psychiatry; 1989 Sept 8‐13; Philadelphia, USA. 1989. DieterleDM , Müller‐SpahnF , AckenheilM . Comparison of zotepine and perazine in schizophrenia. Psychopharmacology1988;96 Suppl 1:340. DieterleDM , Müller‐SpahnF , AckenheilM . Efficacy and tolerance of zotepine in a double‐blind comparison with perazine in schizophrenics [Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten]. Fortschritte der Neurologie und Psychiatrie1991;59 Suppl 1:18‐22. Müller‐SpahnF , DieterleD , AckenheilM . Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double‐blind controlled study [Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind‐kontrollierten Studie]. Fortschritte der Neurologie und Psychiatrie1991;59:30‐5. ">Dieterle 1991</a> favoured perazine in this regard. This might be the result of chance findings due to small sample sizes. The more reasonably sized study by <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a> (191 participants) found no difference between perazine and olanzapine or ziprasidone. Again, further larger trials are needed before definite conclusions can be drawn. </p> </section> <section id="CD002832-sec-0152"> <h5 class="title">2.5 Adverse events</h5> <p>Perazine was not associated with significantly more or fewer adverse events than the drugs in the control groups, but this result might not be a true reflection of effect because the single outcomes were mostly only reported by one or two trials. However, looking at the more global parameter 'leaving the studies earlier because of adverse events', for which five studies could be included, similar rates were found indicating that perazine might generally be as well tolerated as other currently used antipsychotics. Although in each of the haloperidol comparisons perazine was associated with fewer extrapyramidal side‐effects, this could not be confirmed by a meta‐analysis due to poor reporting of data. However, according to three studies comparing perazine with the newer antipsychotics amisulpride and zotepine, perazine had a similar extrapyramidal side‐effect risk. It might therefore be possible that perazine has an atypical profile but, because of the low numbers of participants, more trials are necessary before we can reach a definite conclusion. Unfortunately the comparison of perazine with ziprasidone and olanzapine did not report side‐effect data, thus nothing can be said about the relative effects (<a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>). </p> </section> </section> </section> <section id="CD002832-sec-0153"> <h3 class="title" id="CD002832-sec-0153">Overall completeness and applicability of evidence</h3> <p>The number of included studies is too small to conclusively judge the potential applicability of the obtained results. Trials with small sample sizes lack sufficient power to detect a small to moderate effect, and thus results from such trials are often inconclusive even when a real effect does exist. A review suggested that meta‐analyses based on the summation of small trials should be interpreted as inconclusive, regardless of whether the combined estimate was significant (<a href="./references#CD002832-bbs2-0039" title="Davey SmithG , EggerM . Meta‐analysis: Unresolved issues and future developments. BMJ1998;16:221‐5. ">Davey Smith 1998</a>). </p> </section> <section id="CD002832-sec-0154"> <h3 class="title" id="CD002832-sec-0154">Quality of the evidence</h3> <p>There were major limitations in study quality according to the risk of bias tool. In addition to this tool, only a secondary publication of one study reported that the assessors rating the outcome were independent of the treatment (<a href="./references#CD002832-bbs2-0005" title="KüstnerU , RenfordtE , Müller‐OerlinghausenB . Relationship between neuroleptic medication, handwriting area and therapeutic response. Proceedings of the 14. CINP‐Congress, Florence. 1984. MeyaU , RenfordtE . Can changes in eye‐contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?. Pharmacopsychiatry1986;19:429‐33. RenfordtE , KüstnerU , Müller‐OerlinghausenB . not available [Handschriftveränderungen unter Perazin und Haloperidol]. In: HelmchenH , HippiusH , TölleR editor(s). Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:55‐60. SchmidtLG , SchüsslerG , KappesC‐V , Müller‐OerlinghausenB . A double‐blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mit einer Perazin‐Standard‐Therapie bei akut schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. SchmidtLG , SchüsslerG , KappesV , MühlbauerH , Müller‐OerlinghausenB . A double‐blind comparison of the antipsychotic efficacy of perazine compared to haloperidol [Doppelblind‐Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol]. Arzneimittel‐Forschung1982;32(8):910. SchüsslerG , Müller‐OerlinghausenB , SchmidtLG . not available [Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten]. Therapie mit Neuroleptika ‐ Perazin. Stuttgart, New York: Thieme‐Verlag, 1988:40‐50. ">Schmidt 1982</a>). As the scale‐rated outcomes were largely rated by a person who was unlikely to be disinterested in the final result, all results in this review need to be considered prone to bias. Continuous scale data were often poorly reported. Frequently they lacked explicit statements regarding the denominator or standard deviation, or were only presented in significance tests or within graphs. Three studies used the last observation carried forward (LOCF) approach for those who left the study (<a href="./references#CD002832-bbs2-0003" title="KlimkeA , KlieserE . Clinical relevance of the test dose model for drug choice and response in acute schizophrenia. Pharmacopsychiatry1992;25:85. KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia [Frühes Ansprechen als Kriterium der Medikamentenwahl bei akuter Schizophrenie]. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a>; <a href="./references#CD002832-bbs2-0006" title="SamochowiecJ , TyburaP , WysieckaJP . Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA2009. TyburaP , SamochowiecA , BeszlejA , GrzywaczA , MakM , FrydeckaD , et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacological Reports2012;64:528‐35. ">Tybura 2012</a>), which is prone to bias (<a href="./references#CD002832-bbs2-0061" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>); other studies only presented completer analyses. This did not affect the results of the review because <a href="./references#CD002832-bbs2-0001" title="BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP . Antipsychotic efficacy of trimipramine: double‐blind comparison with a classical neuroleptic. Pharmacopsychiatry1997;30(5):151. BenderS , OlbrichH , HornsteinC , SchöneW , FalkaiP , Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: double‐blind comparison with the phenothiazine perazine. 6th World Congress of Biological Psychiatry. Nice, France, June 22‐27 1997. [MEDLINE: 75029586; PMID 4608707] BenderS , OlbrichHM , FischerW , HornsteinC , SchoeneW , FalkaiP , et al. Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double‐blind comparison with the phenothiazine perazine. Pharmacopsychiatry2003;36(2):61‐9. [EMBASE: 2003210869] Blaeser‐KielG . Schizoaffective disorders ‐ testing of antipsychotic components of trimipramine [Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test]. TW Neurologie Psychiatrie1996;10(10):780‐1. ">Bender 1997</a> is the only study in the first comparison and for <a href="./references#CD002832-bbs2-0003" title="KlimkeA , KlieserE . Clinical relevance of the test dose model for drug choice and response in acute schizophrenia. Pharmacopsychiatry1992;25:85. KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia [Frühes Ansprechen als Kriterium der Medikamentenwahl bei akuter Schizophrenie]. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a> usable data on efficacy outcomes were not available anyway. These limitations led to low or very low quality judgements in several important outcomes in the summary of findings table. </p> </section> <section id="CD002832-sec-0155"> <h3 class="title" id="CD002832-sec-0155">Potential biases in the review process</h3> <p>The evidence presented here is, to the best of our knowledge, complete. However, one can never be certain whether some additional (unpublished) material exists that was not pooled in the analysis. </p> </section> <section id="CD002832-sec-0156"> <h3 class="title" id="CD002832-sec-0156">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other systematic reviews of the effects of perazine in schizophrenia.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002832-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD002832-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002832-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002832-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 1 Leaving the study early." data-id="CD002832-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 1 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 2 Global state: Change over time ‐ no better or deterioration." data-id="CD002832-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 2 Global state: Change over time ‐ no better or deterioration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 3 Mental state: 1a. General ‐ Less than 20% BPRS reduction." data-id="CD002832-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 3 Mental state: 1a. General ‐ Less than 20% BPRS reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 4 Mental state: 1b. General ‐ Less than 30% BPRS reduction." data-id="CD002832-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 4 Mental state: 1b. General ‐ Less than 30% BPRS reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 5 Mental state: 1c. General ‐ BPRS endpoint score ‐ per protocol sample (high=poor)." data-id="CD002832-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 5 Mental state: 1c. General ‐ BPRS endpoint score ‐ per protocol sample (high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 6 Mental state: 1d. General ‐ BPRS change from baseline to endpoint (high=poor)." data-id="CD002832-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 6 Mental state: 1d. General ‐ BPRS change from baseline to endpoint (high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 7 Adverse events: 1. General ‐ at least one adverse event." data-id="CD002832-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 7 Adverse events: 1. General ‐ at least one adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 8 Adverse events: 2. Movement disorder ‐ at least one extrapyramidal side‐effect." data-id="CD002832-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 8 Adverse events: 2. Movement disorder ‐ at least one extrapyramidal side‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 9 Adverse events: 3. Movement disorder ‐ use of antiparkinson medication." data-id="CD002832-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 9 Adverse events: 3. Movement disorder ‐ use of antiparkinson medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Perazine versus placebo, Outcome 10 Sensitivity analysis: fixed effects model ‐ global state no better or worse." data-id="CD002832-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Perazine versus placebo, Outcome 10 Sensitivity analysis: fixed effects model ‐ global state no better or worse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 1 Leaving the study early due to any reason." data-id="CD002832-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 1 Leaving the study early due to any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 2 Global state: 1. No better or deterioration." data-id="CD002832-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 2 Global state: 1. No better or deterioration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 3 Global state: 2. CGI severity score at endpoint (high = poor)." data-id="CD002832-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 3 Global state: 2. CGI severity score at endpoint (high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 4 Global state: 3. GAS endpoint score (low = poor)." data-id="CD002832-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 4 Global state: 3. GAS endpoint score (low = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 5 Mental state: 1a. General ‐ BPRS ‐ no better or deterioration." data-id="CD002832-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 5 Mental state: 1a. General ‐ BPRS ‐ no better or deterioration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 6 Mental state: 1b. General ‐ BPRS endpoint score (high = poor)." data-id="CD002832-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 6 Mental state: 1b. General ‐ BPRS endpoint score (high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 7 Mental state: 1c. General ‐ BPRS endpoint score: separate items (high = poor)." data-id="CD002832-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 7 Mental state: 1c. General ‐ BPRS endpoint score: separate items (high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 8 Mental state: 1d. General ‐ percentage PANSS change from baseline." data-id="CD002832-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 8 Mental state: 1d. General ‐ percentage PANSS change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 9 Mental state: 1e. Specific ‐ BPRS positive symptoms subscore at endpoint (high = poor)." data-id="CD002832-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 9 Mental state: 1e. Specific ‐ BPRS positive symptoms subscore at endpoint (high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0023"> <p> <div class="table" id="CD002832-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rüther 1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean BPRS‐score at endpoint<br/> Perazine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rüther 1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schmidt 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean AMDP‐score at endpoint:<br/> Perazine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schmidt 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 10 Mental state: 2. Unable to use (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD002832-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 11 Adverse events: 1. Movement disorder." data-id="CD002832-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 11 Adverse events: 1. Movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 12 Adverse events: 2. Leaving the study early due to adverse events." data-id="CD002832-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 12 Adverse events: 2. Leaving the study early due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 13 Adverse events: 3. Anticholinergic." data-id="CD002832-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 13 Adverse events: 3. Anticholinergic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 14 Adverse events: 4. Arousal." data-id="CD002832-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 14 Adverse events: 4. Arousal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 15 Adverse events: 5. Abnormal laboratory results." data-id="CD002832-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 15 Adverse events: 5. Abnormal laboratory results. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 16 Adverse events: 6. Cardiovascular." data-id="CD002832-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 16 Adverse events: 6. Cardiovascular.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 17 Adverse events: 7. EEG‐changes." data-id="CD002832-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 17 Adverse events: 7. EEG‐changes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 18 Adverse events: 8. Hypersalivation." data-id="CD002832-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 18 Adverse events: 8. Hypersalivation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 19 Adverse events: 9. Vegetative." data-id="CD002832-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 19 Adverse events: 9. Vegetative.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002832-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/urn:x-wiley:14651858:media:CD002832:CD002832-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_t/tCD002832-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Perazine versus other antipsychotics, Outcome 20 Sensitivity analysis: fixed effects model ‐ global state no better or worse." data-id="CD002832-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Perazine versus other antipsychotics, Outcome 20 Sensitivity analysis: fixed effects model ‐ global state no better or worse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/media/CDSR/CD002832/image_n/nCD002832-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD002832-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: 3 months, 12 months open follow‐up. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia with acute exacerbation.<br/> N = 900.*<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Perazine: dose 300‐800 mg/day. N = 300.</p> <p>2. Haloperidol: dose 2‐15 mg/day. N = 300.</p> <p>3. Olanzapine: dose 5‐20mg/day. N = 300.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving study early (any reason, adverse events, inefficacy).<br/> Service outcomes: hospitalised, time in hospital, attending out patient clinics.<br/> Global impression: Number of participants much improved (CGI)**.<br/> Mental state: PANSS. </p> <p>Quality of life, subjective well‐being.<br/> Adverse events. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>* Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> <br/> ** Primary outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002832-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Perazine versus placebo for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perazine versus placebo for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> perazine versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Perazine versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> <br/> Leaving the study early due to any reason<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>422 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>262 per 1000</b> <br/> (148 to 464) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/> (0.35 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state</b> <br/> change over time (no better or deterioration)<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>467 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>201 per 1000</b> <br/> (107 to 378) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/> (0.23 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mental state</b> <br/> less than 30% BPRS reduction<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>733 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>601 per 1000</b> <br/> (447 to 799) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> <br/> (0.61 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Movement disorders</b> <br/> number of participants receiving antiparkinson medication<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (46 to 864) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.5</b> <br/> (1.04 to 19.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall tolerability</b> <br/> Leaving the studies early due to adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: high risk of attrition bias.<br/> <sup>2</sup> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.<br/> <sup>3</sup> Imprecision: very small number of events.<br/> <sup>4</sup> Indirectness: movement disorders were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Perazine versus placebo for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002832-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Perazine versus other antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Perazine versus other antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> mainly hospital<br/> <b>Intervention:</b> perazine versus other antipsychotics </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Perazine versus other antipsychotics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state</b> <br/> change over time (no better or deterioration)<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (72 to 994) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b> <br/> (0.36 to 4.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall mental state</b> <br/> BPRS endpoint score. Scale from: 0 to 108.<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall mental state in the control groups was<br/> <b>BPRS endpoint score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall mental state in the intervention groups was<br/> <b>0.4 lower</b> <br/> (0.74 to 0.06 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Movement disorders</b> <br/> number of participants receiving antiparkinson medication<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>242 per 1000</b> <br/> (106 to 552) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (0.53 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall tolerability</b> <br/> Leaving the study early due to adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (51 to 240) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/> (0.4 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> <br/> Leaving the studies early due to any reason<br/> Follow‐up: 1‐3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> <br/> (202 to 409) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/> (0.68 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: high risk of reporting bias.<br/> <sup>2</sup> Imprecision: Small number of events.<br/> <sup>3</sup> Imprecision: Very small population size.<br/> <sup>4</sup> Indirectness: adverse events were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events.<br/> <sup>5</sup> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Perazine versus other antipsychotics for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/full#CD002832-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002832-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Perazine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.35, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Inefficacy of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.09, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: Change over time ‐ no better or deterioration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.23, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1a. General ‐ Less than 20% BPRS reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.47, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1b. General ‐ Less than 30% BPRS reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1c. General ‐ BPRS endpoint score ‐ per protocol sample (high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.20 [‐13.20, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1d. General ‐ BPRS change from baseline to endpoint (high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 per protocol analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.1 [‐13.12, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 intent‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.10 [‐13.51, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: 1. General ‐ at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.87, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events: 2. Movement disorder ‐ at least one extrapyramidal side‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.53 [0.79, 230.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: 3. Movement disorder ‐ use of antiparkinson medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [1.04, 19.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Sensitivity analysis: fixed effects model ‐ global state no better or worse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.23, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Perazine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002832-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Perazine versus other antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early due to any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.68, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. No better or deterioration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.36, 4.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. CGI severity score at endpoint (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.01, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 3. GAS endpoint score (low = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.0 [‐17.12, ‐2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1a. General ‐ BPRS ‐ no better or deterioration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.53, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1b. General ‐ BPRS endpoint score (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.92 [1.10, 14.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 1c. General ‐ BPRS endpoint score: separate items (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.74, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 1d. General ‐ percentage PANSS change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [‐2.80, 10.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 1e. Specific ‐ BPRS positive symptoms subscore at endpoint (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.78, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2. Unable to use (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events: 1. Movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.09, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.06, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 neuroleptic malignant syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.53, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.25, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: 2. Leaving the study early due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.40, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: 3. Anticholinergic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.16, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: 4. Arousal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 drowsiness / sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.39, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events: 5. Abnormal laboratory results <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 leukocytosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 increase of transaminases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.67, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events: 6. Cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.12, 5.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 hypotension ‐ orthostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.12, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events: 7. EEG‐changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.04, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse events: 8. Hypersalivation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse events: 9. Vegetative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.73, 3.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Sensitivity analysis: fixed effects model ‐ global state no better or worse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.36, 4.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Perazine versus other antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002832.pub3/references#CD002832-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002832.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002832-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002832-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002832-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002832-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD002832-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD002832-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002832\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002832\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002832\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002832\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002832\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002832.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002832.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002832.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002832.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002832.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720225467"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002832.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720225471"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002832.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfbf94f2f9377',t:'MTc0MDcyMDIyNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 